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Abstract
Background: Prostate cancer (PCa) is the second most common cancer among men. New imaging-modalities
have increased the diagnosed patients with limited number of metastasis after primary curative therapy, introducing
so-called oligometastatic state. Stereotactic body radiotherapy (SBRT) is emerging as a low-toxicity treatment to erase
PCa localizations and postpone androgen deprivation therapy (ADT). A deeper understanding of the predictive role of
biomarkers is desirable for a targeted treatment selection and surveillance programs. The aims of the RADIOSA trial are:
1. Compare SBRT +/− ADT for oligorecurrent-castration-sensitive PCa (OCS-PCa) in terms of efficacy, toxicity and
Quality of Life (QoL).
2. Develop biology/imaging based prognostic tool that allows identifying OCS-PCa subclasses.
Methods: This is a randomized phase II clinical trial, recruiting 160 OCS-PCa in 3 years, with progression-free survival
(PFS) as primary endpoint. Three tasks will be developed:
1. Randomized clinical study (3 years for accrual and 2 years for follow-up and data analysis);
2. Imaging study, including imaging registration and METastasis Reporting and Data System (MET-RADS) criteria;
3. Pre-clinical study, development of a biobank of blood samples for the analysis of neutrophil-to-lymphocyte ratio
and preparatory for a subsequent miRNA profiling.
We aim to determine which arm is justified for testing in a subsequent Phase III trial. A decision-tree algorithm, based
on prognosis, biological phenotype and imaging profile, will be developed.
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Discussion: Recruiting will start in July 2019. SBRT will allow obtaining excellent PFS, local control, QoL and low
toxicity. In SBRT arm, ADT deferral will allow for a drug-holiday, delaying the detrimental impact on QoL. A sufficient
number of blood samples will be collected to perform biological patient profiling. A stratification tool will be established
with an analysis of morphological and functional imaging, based on the use of MET-RADS criteria.
So, in conclusion, RADIOSA aims to define the optimal management of bone/nodal PCa relapses in a SBRT regimen. This
study will increase our knowledge on low-burden metastatic PCa in the era of high precision and high technology
personalized medicine, offering highly effective therapy in terms of clinical outcome and cost-effectiveness.
Trial registration: The RADIOSA study was prospectively registered at clinicaltrials.gov (NCT03940235, May 2019).
Keywords: Prostate cancer, Radiotherapy, Oligometastasis, Androgen deprivation therapy, Stereotatic body radiation
therapy
Background
PCa is the second most common cancer among men in
the world (1.1 million new cases estimated) and death
PCa related (estimated in over 300,000 deaths annually)
correlates with metastatic state [1].
The advent of novel imaging techniques, such as Pros-
tate-Specific Membrane Antigen Positron Emission Tom-
ography (PSMA PET) and Whole-Body Magnetic
Resonance Imaging (WB MRI), allows an increasing an
early detection and diagnosis of metastases after primary
curative treatment. In clinical practice the possibility to
identify a few number of lesions is called “oligometastatic
state” and it is considered an intermediate phase of tumor
spread with limited metastatic capacity [2]. This state
consists of low-volume disease, typically defined as the
presence of up to 3–5 metastases [3] treatable with a local
approach (such as surgery or radiotherapy) either with or
without systemic therapy.
Patients with low-volume or oligometastatic disease
have improved survival compared with those with high-
volume metastases or a disseminated metastatic cancer
[4]. While chemo-hormonal therapy is the standard of
care for men with high-volume metastatic castration-
sensitive PCa [5], in the low-volume metastatic PCa
additional chemo-therapy did not demonstrate survival
benefit [6], so SBRT is emerging as a promising low-tox-
icity treatment option for oligometastases both at diagno-
sis and recurrence [7]. Small-volume high-dose SBRT
limited to metastatic site might potentially eliminate all
macroscopic cancer foci prolonging the progression-
free interval and postponing ADT. The aim of SBRT in
this setting is to achieve local control and delay pro-
gression, and thereby postpone the need for further
treatment.
Moreover, an open question in this framework is the
patient QoL, to be evaluated in the balance of oligome-
tastatic disease diagnosis, less treatment option and
additional ADT-induced side effects. A deeper under-
standing of the predictive role of biomarkers is desir-
able for a targeted treatment selection and proper
surveillance programs. The limitation associated with
the use of the prostate-specific antigen (PSA) as diag-
nostic and follow-up marker stimulated significant in-
vestigations of several novel biological markers, such as
blood-based parameters, microRNAs and cell-free DNA
[8, 9]. However, this new approach requires a large
amount of coherently collected data to give reliable and
univocal results.
A further research frontier is the role of imaging in this
setting of patients. Recently, the role of WB MRI has been
proposed as a suitable solution for tumor detection and
therapy evaluation in this setting of patients with perform-
ance at least comparable with the Choline positron emis-
sion tomography/computed tomography Ch-PET/CT [10].
Overall, clear-cut data and tools to guide a consensus
about the optimal therapeutic choice for the individual
clinical situation are not validated and the standard of
care to recurrent PCa remains ADT, with significant side
effect and deterioration of QoL [11].
Methods/design
Aim, design, and setting of the study
The present research project aims to define the optimal
management of bone or nodal PCa recurrences in a SBRT
regimen. As a final result, a decision-tree algorithm, based
on prognosis, biological phenotype and imaging profile,
will be obtained as a clinically useful tool.
This study will move forward our knowledge on low-
burden metastatic PCa in the era of high-precision and
high technology personalized medicine, offering highly
effective therapy in terms of clinical outcome and cost
effectiveness. The aim is to compare time to progression
between the two study arms: SBRT only or SBRT and
ADT. RADIOSA will be developed during the 5 years of
the project and it is divided in two main phases.
Study population
Participant characteristics
RADIOSA is a prospective monocentric randomized
phase II study in which oligorecurrent PCa patients (1–3
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lesions) are randomized to two treatments and the re-
sults with the longest time to progression is selected for
further study [12].
Eligibility criteria
The inclusion criteria are as follows:
1) Histologically proven initial diagnosis of
adenocarcinoma of the prostate
2) Biochemical relapse of PCa following radical local
prostate treatment (radical prostatectomy, primary
radiotherapy or radical prostatectomy +/− prostate
bed adjuvant/salvage radiotherapy) +/− ADT
according to the European Association of Urology
(EAU) guidelines 2016 [13] or after any salvage
therapy if biochemical progression is diagnosed in
the context of castration sensitive PCa
3) Nodal relapse in the pelvis, extra-regional nodal
relapse (M1a), bone metastases (M1b) on Ch-PET/
CT or WB MRI with a maximum of 3 lesions
4) Serum testosterone level > 50 ng/dl at the time of
randomization (castration sensitive PCa)
5) Eastern Cooperative Oncology Group (ECOG)
performance status 0–1
6) Age ≥ 18 years
7) Ability to complete questionnaires about QoL
8) Written informed consent signed.
The exclusion criteria are as follows:
1) Presence of visceral metastases
2) More than three metastases
3) Inability to complete questionnaires about QoL
4) Previous invasive cancer (within 3 years before the
prostate cancer diagnosis) apart from non-
melanoma skin malignancies;
5) Serious concomitant comorbidities or
contraindication to SBRT and/or ADT
6) Mental diseases that cannot ensure valid informed
consent
Methods of recruitment and random allocation
In phase 1 a hundred sixty consecutive patients will be
enrolled at the Division of Radiation Oncology at the
European Institute of Oncology (IEO), Milan, Italy within
a multidisciplinary uro-oncology board.
There will be a 1:1 randomization between Arm 1 and
Arm 2. Patients will be stratified according to PSA doubling
time (≤3 vs. > 3months) [14, 15], initial localization of me-
tastases (node vs bone) and diagnostic imaging (PET vs.
MRI) [Fig. 1].
The patients will be randomized in either:
– ARM 1: salvage SBRT for lymph nodes and/or bone
metastases. All the radiologically documented
lesions will be treated simultaneously.
– ARM 2: salvage SBRT (as described for ARM 1) + 6-
month ADT (luteinizing hormone-releasing
hormone (LHRH) agonist or antagonist). ADT
should start within 1 week before the start of SBRT.
Phase 2 is complementary to Phase 1. After SBRT com-
pletion, patients will be followed-up with PSA and testos-
terone measurements every 3months and with clinical
examination at 3 and 6months and every 6months there-
after. Questionnaires for the assessment of QoL will be
administered within 2 weeks prior to randomization, at 3
and 12months, and yearly thereafter.
Blood and plasma samples for biological evaluation and
randomization of patients, at 3 months from completion
of treatment and at clinical relapse. The samples will be
stored in the “European Institute of Oncology Biobank”.
Acute and late toxicity will be assessed according to the
Common Toxicity Criteria for adverse events (CTCAE)
toxicity criteria v4.3 [16], evaluated at 1 (acute toxicity)
and at 3–6months after the end SBRT and yearly after-
wards (late toxicity). Time to castration-resistant disease
will be assessed as time to start a systemic therapy (testos-
terone evaluation). A timeline of this study is summarized
in Table 1.
Moreover, a decision-tree algorithm, based on prognosis,
imaging profile and biological phenotype will be developed:
it will be addressed to identify recurrent PCa that remains
oligometastatic and those that rapidly progress to a poly-
metastatic phase, thus allowing in the future to stratify
patients who might avoid, or at least delay ADT, or not.
Data will be published at the end of the end of enroll-
ment (2024).
Treatment
Within 35 days prior to randomization, either a WB MRI
or a Ch-PET/CT is mandatory to confirm a diagnosis of
oligorecurrent disease, with a maximum of 3 pelvic/extra-
pelvic lymph nodes and/or bone metastases, and to ex-
clude visceral disease.
According to SBRT technique, high doses will be deliv-
ered to small volumes in few fractions (≤5). In our frame-
work, a schedule of 30 Gy in 3 fractions every other day
(equivalent dose EQD2 = 98.6 Gy, considering α/β = 1.5
Gy), or equivalent regimens depending on disease site
location will be used. Treatment planning and delivery will
be performed using dedicated systems, such as Iplannet-
Vero (Brainlab-Mitsubishi) and Multiplan-CyberKnife
(Accuray), Eclipse-Trilogy (Varian) and Tomotherapy
(Accuray). As far as image-guidance is concerned, Vero,
Trilogy and Tomotherapy use a pre-treatment cone-beam
CT whereas CyberKnife is based on intrafraction X-Rays.
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Thus, CyberKnife needs fiducials or spine tracking. Cyber-
Knife is preferred when particular attention to critical
structures is required and spine tracking is possible. Strict
quality assurance protocols will be implemented to ensure
the accuracy in dose delivery.
Endpoints of the study
The primary objective is to compare the progression-
free survival (PFS) defined as the absence of new meta-
static lesions (local, regional or distant) between the
two arms.
Fig. 1 Study design
Table 1 Timeline of the study
Screening 2 weeks within
randomization
1 months after
end of RT
3 months after
end of RT
Every 3
months
12months
after end of RT
Every
year
Biochimical
relapse
Clinical
relapse
Physical examination x x x
PSA/testosterone x x x x
GS x
Previous treatments for PCa x
ECOG score x
Comorbidities x
Imaging x
Blood tests (NLR) x
Serum and plasma
collection
x x x
Acute toxicity assessment x
Late toxicity assessment x
QoL x x x x x
Cho-PET/TC or RM-WB x x
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The secondary endpoints are as follows:
1) comparison of overall survival (OS)
2) biochemical progression-free survival (BPFS)
3) ADT-free survival
4) local control
5) treatment-induced acute and late toxicity
6) time to castration-resistant disease
7) QoL between the two arms
8) development of a dedicated biobanking (collection
of plasma and serum) for further biological
investigation of predictive/diagnostic factors for
personalized treatment
9) the preliminary evaluation of prognostic biomarkers
10) the correlation between imaging-derived parameters
and treatment outcome
The present research project will be developed for 60
months, during which specific milestones will be achieved
and documented.
Discontinuation of the treatment/ disease progression
In case of biochemical progression (defined according
to the EAU guidelines [13]) after SBRT, a new imaging
scan should be considered: a WB MRI or Ch-PET/CT
scan at time of biochemical progression or symptomatic
progression and 6-montly afterwards until clinical
progression will be performed. Further treatments
(including ADT or other treatments according to the
institutional policy) should not be started for biochem-
ical progression without documented clinical progres-
sion on WB MRI or Ch-PET/CT. Repeated SBRT is
allowed.
Ethical consideration and study registration
The study will be performed in accordance with the Dec-
laration of Helsinki and will comply to the International
Conference on Harmonization and Good Clinical Practice.
All possible treatments and examinations for CRPC are
undertaken after obtaining written informed consent from
the patients before registration. This trial was supported
by the research grants from the Italian Association for
Cancer Research (AIRC) IG-22159.
The RADIOSA study was approved by the Ethics
Committee of “IRCCS Istituto Europeo di Oncologia
and Centro Cardiologico Monzino” (IEO-997).
The study has been registered at clinicaltrials.gov
(NCT03940235).
Calculation of the target sample size
The main endpoint of this study is time to progression
(local, biochemical and clinical progression) in oligome-
tastatic PCA patients. We designed a randomized phase
II selection study in which patients are randomized to
two treatments and the results with the longest time to
progression is selected for further study [12]. The aim is
to compare time to progression between the two study
arms: SBRT only or SBRT and hormonotherapy, with
α = 0.10 and β = 0.20. It is estimated that the median
delay to start palliative ADT after metastasis-directed
therapy is approximately 24 months [17]. In order to de-
tect a 12-month difference in the main endpoint from
12 to 24 months, a total of 152 patients will be needed,
using a two-sided hypothesis based on the F distribution.
Assuming a 5% rate of loss to follow-up, a total of 160
patients will be accrued over 36 months with 24months
of additional follow-up. We expect an accrual rate of 53
patients per year.
Discussion
Recently, the concept of ADT-free survival, intended as
the time to the delayed start of ADT, in order to spare
the related negative side effect, such as the increased
occurrence of cardiovascular events and metabolic
syndrome, that significantly affect the QoL [7]. The aim
of SBRT in this setting is to achieve local control and
delay progression, and thereby postpone the need for
further treatments.
From the clinical standpoint, the emergence of castra-
tion resistance is usually a nearby antecedent of wide-
spread disease progression, visceral involvement and
death from PCa. Therefore, preservation of the respon-
siveness to ADT is crucial in the long-term management
of patients with metastatic PCa.
Also, from socio-economic point of view, 12 months
without ADT can be considered a consistent gain for the
National Health System, especially considering the rele-
vant costs of the new and spreading anti-androgens like
Abiraterone and Enzalutamide [5].
Current knowledge is mainly based on retrospective
and non-randomized studies, thus suffering from hetero-
geneous population (i.e., due to biased patient selection)
and inappropriate sample power [18].
It is evident that also in the setting of metastatic PCa,
prostatic definitive radiotherapy could find a place. First
data derived from retrospective trials by Löppenberg et
al. and Rusthoven et al. demonstrated an improvement
in OS for patients who underwent radiation therapy tar-
geting the prostate in comparison to those who received
only hormonal treatment [19, 20].
The oligometastatic concept has been developed in the
last years and recent trials show interesting results on
adding local treatments (LCT) (such as radiotherapy or
surgery) at standard therapy. Particularly, it is important
to mention the results achieved by Gomez and Palma.
Gomez et al., that conducted a randomized phase II trial
on oligometastatic NSCLC, reporting a significant PFS
benefit with LCT (both radiotherapy or surgery) vs
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maintenance systemic therapy (14.4 months vs 4.4
months respectively) [18]. In another randomized phase
II trial, named SABR-COMET, a benefit in OS in the
SBRT arm for the oligometastatic setting compared to
palliative treatment was demonstrated (41 months vs 28
months) [21].
The HORRAD study is a multi-centric prospective
study, randomized controlled trial recruiting bone meta-
static PCa patients. The objective was to compare irradi-
ation of primary prostatic tumor with external beam
radiation therapy with ADT versus ADT only. The trial
revealed no significant difference in OS. However, sub-
group analysis suggests that radiotherapy to the prostate
actually improves OS in patients with a low metastatic
burden (< 5 bone lesions) [22].
More recently, subgroup analysis of patients with a
low metastatic burden from STAMPEDE (a phase 3 ran-
domized controlled trial) showed that OS was improved
with radiotherapy, giving a three-year survival of 81% in
these men, compared to 73% in the standard treatment
group [5].
For Murphy et al., the approach to metastatic PCa
“catching ‘em all”, or “pokemet”, must be considered
experimental [23]. Also, in this setting, data from retro-
spective studies suggest that cancer specific and OS is
improved with Metastasis-directed therapy (MDT) com-
pared to the standard of care. MDT treatment regimens
vary with different radiotherapy techniques, doses, and
volumes [3]. Among prospective studies, STOMP and
ORIOLE trials are worth mentioning [24, 25].
However, despite encouraging data, some authors re-
main skeptical that MDT will delay the use of ADT.
Moreover, this argument is a weak endpoint compared
to PFS or OS especially given that timing for using hor-
monotherapy remains controversial.
Whereas the use of systemic therapy was largely inves-
tigated by several large clinical trials, currently, limited
studies focus on metastasis-directed SBRT. These stud-
ies, despite short follow-up that limited the evaluation of
OS and cancer-specific survival, showed that metastasis-
directed SBRT is a safe treatment, reaching a high local
control (about 95%) with low-grade toxicity, generally
limited to gastro-intestinal effects [3, 26–29].
So, new biomarkers are mandatory to help determin-
ing the natural history of the disease and to select the
patients who could actually benefit from MDT. The
discovery of miRNA seems to give a start of answers to
many questions that arise.
Recent studies have demonstrated that miRNAs influ-
ence many stages of carcinogenesis and can effectively
modulate tumor radiosensitivity at different levels, by
affecting targets involved in DNA damage repair, cell
cycle checkpoint, apoptosis, signal transduction pathways
and tumor microenvironment. Thus, the identification of
miRNA involved in DNA damage radiation response
is not excluded and might lead to the use of Poly
(ADP-ribose) polymerase (PARP) inhibitors in the
near future [26].
In a recent published study by Pitroda PS et al., a mo-
lecular basis (such as mi-RNA profiling) for oligometa-
static state in colorectal liver metastasis was identified in
order to predict clinical outcome and establish clinical
risk factors associated with long-term survival following
hepatic resection [30].
According to Formosa et al. a series of miRNAs called
oligomers would be typical of oligometastatic diseases,
and thus have a role in the developmentof the oligome-
tastatic state and the transition from an oligometastatic
state to a polymetastatic disease [31].
Overall, data and tools to guide an optimal therapeutic
choice in this setting are not validated and the standard
of care to recurrent PCa remains ADT, with significant
side effects and deterioration of QoL [10]. To address a
larger consensus on oligorecurrent PCa management,
randomized clinical trials selecting homogeneous patient
population are needed.
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